Xencor (XNCR) Competitors $14.95 +0.85 (+6.03%) Closing price 04:00 PM EasternExtended Trading$15.00 +0.06 (+0.37%) As of 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XNCR vs. MIRM, LNTH, ADMA, ACAD, ZLAB, QURE, CGON, AAPG, TLX, and APLSShould you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), ADMA Biologics (ADMA), ACADIA Pharmaceuticals (ACAD), Zai Lab (ZLAB), uniQure (QURE), CG Oncology (CGON), Ascentage Pharma Group International (AAPG), Telix Pharmaceuticals (TLX), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry. Xencor vs. Its Competitors Mirum Pharmaceuticals Lantheus ADMA Biologics ACADIA Pharmaceuticals Zai Lab uniQure CG Oncology Ascentage Pharma Group International Telix Pharmaceuticals Apellis Pharmaceuticals Xencor (NASDAQ:XNCR) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership. Do analysts rate XNCR or MIRM? Xencor currently has a consensus target price of $24.22, suggesting a potential upside of 62.02%. Mirum Pharmaceuticals has a consensus target price of $76.91, suggesting a potential upside of 3.34%. Given Xencor's higher probable upside, equities research analysts clearly believe Xencor is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xencor 2 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.64Mirum Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00 Is XNCR or MIRM more profitable? Mirum Pharmaceuticals has a net margin of -13.65% compared to Xencor's net margin of -121.52%. Mirum Pharmaceuticals' return on equity of -24.76% beat Xencor's return on equity.Company Net Margins Return on Equity Return on Assets Xencor-121.52% -25.75% -18.19% Mirum Pharmaceuticals -13.65%-24.76%-8.50% Which has preferable valuation and earnings, XNCR or MIRM? Mirum Pharmaceuticals has higher revenue and earnings than Xencor. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXencor$146.93M7.26-$232.62M-$2.40-6.23Mirum Pharmaceuticals$429.16M8.71-$87.94M-$1.21-61.50 Which has more risk & volatility, XNCR or MIRM? Xencor has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Does the media favor XNCR or MIRM? In the previous week, Xencor had 7 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 19 mentions for Xencor and 12 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.82 beat Xencor's score of 0.44 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 2 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Mirum Pharmaceuticals 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMirum Pharmaceuticals beats Xencor on 11 of the 15 factors compared between the two stocks. Get Xencor News Delivered to You Automatically Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XNCR vs. The Competition Export to ExcelMetricXencorMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.07B$3.02B$6.13B$10.46BDividend YieldN/A57.77%5.73%4.78%P/E Ratio-6.2322.9185.1527.20Price / Sales7.26612.09574.61178.68Price / CashN/A172.6337.3961.86Price / Book1.555.4112.396.65Net Income-$232.62M$33.06M$3.32B$276.79M7 Day Performance14.47%-2.27%-0.24%-1.51%1 Month Performance73.43%11.49%9.56%5.46%1 Year Performance-30.53%-3.25%71.67%36.25% Xencor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XNCRXencor3.6991 of 5 stars$14.95+6.0%$24.22+62.0%-33.3%$1.07B$146.93M-6.23280Analyst ForecastGap UpHigh Trading VolumeMIRMMirum Pharmaceuticals3.2175 of 5 stars$72.17-0.7%$76.50+6.0%+91.9%$3.65B$336.89M-59.64140Positive NewsAnalyst ForecastAnalyst RevisionLNTHLantheus4.5458 of 5 stars$54.59+2.0%$74.50+36.5%-49.5%$3.64B$1.53B14.52700Trending NewsAnalyst RevisionADMAADMA Biologics3.5878 of 5 stars$14.55+0.1%$27.67+90.1%-9.0%$3.47B$426.45M16.92530News CoverageACADACADIA Pharmaceuticals3.9246 of 5 stars$20.06flat$29.12+45.2%+45.8%$3.38B$957.80M15.08510Analyst ForecastZLABZai Lab2.7445 of 5 stars$31.23+3.3%$56.35+80.4%+18.6%$3.38B$398.99M-15.311,869News CoveragePositive NewsQUREuniQure2.9872 of 5 stars$62.02+0.7%$71.75+15.7%+1,014.0%$3.38B$27.12M-15.82500CGONCG Oncology2.1643 of 5 stars$42.96-0.7%$58.82+36.9%+15.7%$3.30B$1.14M-24.2761AAPGAscentage Pharma Group InternationalN/A$36.45+4.3%N/AN/A$3.26B$390.60M0.00600TLXTelix Pharmaceuticals3.8799 of 5 stars$9.54-0.3%$21.00+120.1%N/A$3.24B$516.72M0.00N/ATrending NewsAnalyst RevisionAPLSApellis Pharmaceuticals4.283 of 5 stars$24.14-3.9%$33.29+37.9%-9.8%$3.17B$781.37M-13.26770Trending NewsAnalyst ForecastInsider TradeAnalyst Revision Related Companies and Tools Related Companies Mirum Pharmaceuticals Alternatives Lantheus Alternatives ADMA Biologics Alternatives ACADIA Pharmaceuticals Alternatives Zai Lab Alternatives uniQure Alternatives CG Oncology Alternatives Ascentage Pharma Group International Alternatives Telix Pharmaceuticals Alternatives Apellis Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XNCR) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredIs *BSEM* Oversold??BioStem Technologies Inc. (OTC: BSEM) is emerging as one of the most exciting MedTech stories of 2025. The com...Huge Alerts | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
